Adding noninsulin antidiabetic drugs to metformin therapy for type 2 diabetes

JAMA

Volumn 304, Issue 4, 2010, Pages 405-

  Giugliano, Dario ^a   Esposito, Katherine ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA;

ADD ON THERAPY; CLINICAL TRIAL; DRUG DOSE TITRATION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PLACEBO EFFECT; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 77954960907     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1020     Document Type: Letter

References (3)

1. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410-1418.
2. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
3. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301(8):831-841.